Nature Communications (May 2020)
Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures
- Robert Vander Velde,
- Nara Yoon,
- Viktoriya Marusyk,
- Arda Durmaz,
- Andrew Dhawan,
- Daria Miroshnychenko,
- Diego Lozano-Peral,
- Bina Desai,
- Olena Balynska,
- Jan Poleszhuk,
- Liu Kenian,
- Mingxiang Teng,
- Mohamed Abazeed,
- Omar Mian,
- Aik Choon Tan,
- Eric Haura,
- Jacob Scott,
- Andriy Marusyk
Affiliations
- Robert Vander Velde
- Department of Cancer Physiology, H Lee Moffitt Cancer Centre and Research Institute
- Nara Yoon
- Department of Translational Hematology and Oncology Research, Cleveland Clinic
- Viktoriya Marusyk
- Department of Cancer Physiology, H Lee Moffitt Cancer Centre and Research Institute
- Arda Durmaz
- Department of Translational Hematology and Oncology Research, Cleveland Clinic
- Andrew Dhawan
- Department of Translational Hematology and Oncology Research, Cleveland Clinic
- Daria Miroshnychenko
- Department of Cancer Physiology, H Lee Moffitt Cancer Centre and Research Institute
- Diego Lozano-Peral
- Department of Cancer Physiology, H Lee Moffitt Cancer Centre and Research Institute
- Bina Desai
- Department of Cancer Physiology, H Lee Moffitt Cancer Centre and Research Institute
- Olena Balynska
- Department of Cancer Physiology, H Lee Moffitt Cancer Centre and Research Institute
- Jan Poleszhuk
- Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences
- Liu Kenian
- Department of Pathology, H Lee Moffitt Cancer Centre and Research Institute
- Mingxiang Teng
- Department of Biostatistic and Bioinformatics, H Lee Moffitt Cancer Centre and Research Institute
- Mohamed Abazeed
- Department of Translational Hematology and Oncology Research, Cleveland Clinic
- Omar Mian
- Department of Translational Hematology and Oncology Research, Cleveland Clinic
- Aik Choon Tan
- Department of Biostatistic and Bioinformatics, H Lee Moffitt Cancer Centre and Research Institute
- Eric Haura
- Department of Thoracic Oncology, H Lee Moffitt Cancer Centre and Research Institute
- Jacob Scott
- Department of Translational Hematology and Oncology Research, Cleveland Clinic
- Andriy Marusyk
- Department of Cancer Physiology, H Lee Moffitt Cancer Centre and Research Institute
- DOI
- https://doi.org/10.1038/s41467-020-16212-w
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 13
Abstract
Acquired resistance to cancer therapies reflects the ability of cancers to adapt to therapy-imposed selective pressures. Here, the authors elucidate the dynamics of developing resistance to ALK inhibitors in an ALK+ lung cancer cell line showing that resistance originates from drug-specific tolerant cancer cells and it develops as a gradual adaptation.
